Want Exposure to the Fast-Growing Drone Market? Buy These 2 Stocks.

The global drone market is projected to more than double from $69B to $148B by 2036, driven by wartime demand for low-cost combat drones. The Pentagon’s $1.1B program targets mass-producing $3,000–$5,000 drones and scaling via merit-based field trials, including “gauntlets” that Red Cat’s Teal Drones has advanced into (next test: delivering 120 kamikaze drones in a five-week window). Kratos (KTOS) participated in early gauntlets but was eliminated after phase two, while its AI wingman XQ-58A Valkyrie is being developed with the U.S. Marine Corps at an estimated $3M–$4M versus $80M–$100M for an F-35, supporting a more established defense backlog outlook.

Analysis

The durable winners are likely not the smallest drone builders, but the firms that sit one layer higher in the kill chain: systems integration, secure comms, EW, training, and sustainment. Qualification events can create sharp sentiment spikes for RCAT, but that does not automatically translate into repeatable gross profit if production ramps require inventory, working capital, and new capital raises.

The market is probably underestimating how quickly this becomes a commoditization story for hardware and overestimating how much of the budget flows to pure-play airframes. If procurement really accelerates, incumbent defense primes such as NOC and platform-adjacent names like KTOS should capture the steadier revenue stream, while smaller names face a winner-take-most selection process and balance-sheet pressure. The key second-order effect is supplier leverage: the scarce value should migrate to autonomy software, sensors, radios, and battlefield networking rather than the drone chassis itself.

Near term, RCAT can keep trading as an event-driven momentum name into the next trial milestone, but the risk/reward worsens if investors price in a contract before production is proven. Over 1-3 months, the main falsifier is any evidence of missed delivery timing, dilution, or a procurement process that reverts to slower incumbent-friendly channels. Over 6-18 months, the thesis only works if the Pentagon converts trials into multi-lot awards at scale; otherwise the category stays thematic, not economically meaningful.

Key Decisions for Investors

• Long KTOS / short RCAT for 2-4 months: express the view that scalable defense revenue and program breadth matter more than trial-driven hype; target relative outperformance if RCAT needs capital or misses production timelines.
• Buy NOC on weakness as a lower-beta way to own the drone adoption cycle; the upside is less explosive, but the downside is better protected if procurement shifts to incumbent-integrated systems.
• If trading RCAT, use call spreads rather than outright stock and only on pullbacks ahead of the next milestone; the risk is binary execution failure and dilution if manufacturing scale lags.
• Set a hard watch item on RCAT for evidence of a real purchase order, not just another qualification pass; if no contract conversion by year-end, the narrative premium should compress.
• Avoid chasing the basket on headline strength; prefer names with backlog or integration leverage over pure-play drone OEMs, where operating leverage is still unproven.